ELITE PHARMACEUTICALS INC /NV/ (ELTP)

↓ Download CSV

CIK 0001053369 · OTC · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated NJ
  • Fiscal year ends Mar 31

In fiscal 2025, ELITE PHARMACEUTICALS INC /NV/ reported revenue of $84.04M, up 48.4% from the prior year. The company ran a net loss, with a net margin of -5.1% and a gross margin of 47.7%. It held $96.39M in total assets against $42.87M in total liabilities.

Key ratios (FY2025)

47.7%
Gross margin
23.3%
Operating margin
-5.1%
Net margin
-8.1%
Return on equity
+48.4%
Revenue growth (YoY)
Metric (FY)2025202420232022202120202019201820172016
Revenue$84.04M$56.63M$34.16M$32.26M$25.38M
Cost of Revenue$43.96M$30.27M$17.56M$17.47M$13.51M$10.02M$4.70M$3.51M$5.90M$4.48M
Gross Profit$40.09M$26.36M$16.59M$14.80M$11.87M$7.98M$2.87M$3.95M$3.74M$8.01M
Operating Income$19.60M$10.79M$3.68M$5.07M$2.10M-$2.29M-$9.16M-$9.05M-$7.36M-$8.32M
Net Income-$4.31M$20.11M$3.56M$8.90M$5.09M-$2.24M-$9.28M-$3.67M$3.81M-$683.0K
EPS (Diluted)$0.00$0.02$0.00$0.01$0.00$0.00$-0.01$-0.01$-0.01$-0.01
Total Assets$96.39M$83.65M$40.90M$35.15M$26.19M$24.96M$24.40M$30.88M$34.31M$31.67M
Total Liabilities$42.87M$26.07M$11.94M$9.93M$10.04M$14.30M$13.01M$12.41M$8.65M$20.51M
Shareholders' Equity$53.52M$57.58M$28.96M$25.22M$16.15M$10.66M-$2.51M$4.57M$25.66M-$33.12M
Cash & Equivalents$7.11M$7.83M$8.54M$3.19M$1.13M$2.28M$7.18M$10.59M$11.51M
Operating Cash Flow$7.46M-$3.24M$3.34M$6.51M$3.19M-$1.79M-$6.79M-$4.81M-$7.88M-$2.77M
Capital Expenditures$1.63M$809.7K$5.74M$498.6K
Shares Outstanding1.07B1.07B1.01B1.01B1.01B840.40M824.85M802.53M927.93M711.44M